Miplyffa Alternatives Compared
Miplyffa (arimoclomol) | Aqneursa (levacetylleucine) | Miglustat |
|
---|
Miplyffa (arimoclomol) | Aqneursa (levacetylleucine) | Miglustat |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Niemann-Pick Disease. Miplyffa may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Niemann-Pick Disease. Aqneursa may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Niemann-Pick Disease, Gaucher Disease, Pompe Disease. Miglustat may also be used for purposes not listed in this medication guide. |
Related suggestions Niemann-Pick Disease
|
|||||||||||||||||||||||
More about Miplyffa (arimoclomol) | More about Aqneursa (levacetylleucine) | More about Miglustat | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
Miglustat has an average rating of 8.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Miplyffa side effects |
View all Aqneursa side effects |
View all Miglustat side effects |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
||||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Miplyffa prices |
View all Aqneursa prices |
View all Miglustat prices |
||||||||||||||||||||||||
Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
N/A |
N/A |
Opfolda, Yargesa, Zavesca | ||||||||||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
4 hours |
1 hour |
7 hours |
||||||||||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 8 drugs are known to interact with Miplyffa:
|
A total of 84 drugs are known to interact with Aqneursa:
|
A total of 1 drugs are known to interact with Miglustat:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
September 20, 2024 |
N/A |
July 31, 2003 |
||||||||||||||||||||||||
WADA Class View classifications | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient Resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.